XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Equity
6 Months Ended
Jun. 30, 2022
Equity  
Equity

13. Equity

The changes in shareholders’ equity for the three and six months ended June 30, 2022 were as follows:

    

Additional

    

    

Total

Common Stock

 

Paid- In

Treasury Stock

Accumulated

 

Shareholders’

Shares

    

Amount

 

Capital

Shares

Amount

 

Deficit

 

Equity

Balance, December 31, 2021

35,806,119

$

36

$

502,095

(2,150,717)

$

(42,861)

$

(256,342)

$

202,928

Exercise of common stock options

190,074

3,261

3,261

Issuance for employee stock purchase plan

13,421

203

203

Vesting of RSUs and PSUs

563,050

Shares withheld for employee taxes upon vesting of RSUs and PSUs

(191,667)

(3,382)

(3,382)

Share repurchases from Accelerated Share Repurchase ("ASR") agreement

5,000

(307,132)

(5,000)

Stock-based compensation

6,135

6,135

Net loss

(13,069)

(13,069)

Balance, March 31, 2022

36,380,997

$

36

$

513,312

(2,457,849)

$

(47,861)

$

(269,411)

$

196,076

Exercise of common stock options

102,283

1,545

1,545

Vesting of RSUs and PSUs

111,056

1

1

Shares withheld for employee taxes upon vesting of RSUs and PSUs

(26,506)

(511)

(511)

Stock-based compensation

5,692

5,692

Net loss

(5,191)

(5,191)

Balance, June 30, 2022

36,567,830

$

37

$

520,038

(2,457,849)

$

(47,861)

$

(274,602)

$

197,612

The changes in shareholders’ equity for the three and six months ended 2021 were as follows:

    

Additional

    

    

Total

Common Stock

 

Paid- In

Treasury Stock

Accumulated

 

Shareholders’

Shares

    

Amount

 

Capital

Shares

Amount

 

Deficit

 

Equity

Balance, December 31, 2020

34,612,054

$

35

$

519,143

$

$

(333,147)

$

186,031

Cumulative effect adjustment for adoption of ASU 2020-06

(44,777)

5,288

(39,489)

Exercise of common stock options

289,164

4,102

4,102

Issuance for employee stock purchase plan

24,630

358

358

Vesting of RSUs and PSUs

413,538

Shares withheld for employee taxes upon vesting of RSUs and PSUs

(135,562)

(3,508)

(3,508)

Stock-based compensation

6,879

6,879

Net income

15,662

15,662

Balance, March 31, 2021

35,203,824

$

35

$

482,197

$

$

(312,197)

$

170,035

Exercise of common stock options

273,127

1

4,092

4,093

Vesting of RSUs and PSUs

65,107

Shares withheld for employee taxes upon vesting of RSUs and PSUs

(18,141)

(421)

(421)

Stock-based compensation

6,516

6,516

Net income

72,843

72,843

Balance, June 30, 2021

35,523,917

$

36

$

492,384

$

$

(239,354)

$

253,066

Common Stock

In May 2015, the Company adopted the Amended and Restated 2014 Stock Incentive Plan (the “Plan”), under which an aggregate of 2,700,000 shares of common stock were authorized for issuance to employees, officers, directors, consultants and advisors of the Company, plus an annual increase on the first day of each fiscal year until the expiration of the Plan equal to 4% of the total number of outstanding shares of common stock on December 31st of the immediately preceding calendar year (or a lower amount as otherwise determined by the Company’s board of directors (“Board of Directors”) prior to January 1st). As of June 30, 2022, there were 1,871,810 shares of common stock available for issuance pursuant to the Plan. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options and non-qualified options, restricted stock awards, restricted stock units and performance stock units. The Company’s qualified incentive stock options, non-qualified options and restricted stock units generally vest ratably over a four-year period of service. The stock options generally have a ten-year contractual life and, upon termination, vested options are generally exercisable three months following the termination date, while unvested options are forfeited immediately upon termination. Refer to Note 14, Stock-based Compensation, for more information.

Warrants

As of June 30, 2022, the warrant issued to Assertio in November 2018 was the Company’s only outstanding warrant. In connection with the Third Amendment to the Nucynta Commercialization Agreement, the Company issued a warrant to Assertio to purchase 1,041,667 shares of common stock of the Company at an exercise price of $19.20 per share. The terms of the warrant are fixed, with the exception of customary adjustments for changes in the Company’s capitalization. The warrant may only be settled with the issuance of shares of common stock upon exercise and will expire in November 2022.

Share Repurchases

In August 2021, the Company’s board of directors authorized a share repurchase program to repurchase up to $100,000 of outstanding shares of the Company’s common stock at any time or times through December 31, 2022 (the “Repurchase Program”). The Repurchase Program permits the Company to effect repurchases through a variety of methods, including open-market purchases (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, or otherwise in compliance with Rule 10b-18 of the Exchange Act. Shares repurchased under the Repurchase Program will return to the Company’s pool of authorized but unissued shares available for reissuance. The timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The Repurchase Program can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future.

In October 2021, the Company’s board of directors authorized an accelerated share repurchase program (the “ASR Program”) to repurchase $25,000 of the Company’s common stock, as part of the Company’s existing $100,000 Repurchase Program. Under the terms of the Company's ASR agreement with an investment bank (the “ASR Agreement”), the Company paid $25,000 on November 15, 2021, and received 1,026,694 shares, representing 80% of the upfront payment on a price per share of $19.48, the closing price on the date the ASR Agreement was executed. The remaining shares purchased by the Company was based on the volume-weighted average price of its common stock through January 7, 2022, minus an agreed upon discount between the parties. On January 7, 2022, the ASR Agreement settled, and the Company received an additional 307,132 shares, bringing the total shares repurchased pursuant to the ASR Agreement to 1,333,826.

As of June 30, 2022, the Company repurchased 2,457,849 shares at a weighted-average price of $19.47 per share for a total of $47,861 under the Repurchase Program and the cost of repurchased shares were recorded as treasury stock in the condensed consolidated Balance Sheet. As of June 30, 2022, $52,139 remained available for share repurchases under the Repurchase Program.